3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Oropharyngeal Neoplasms
1
Lymphoma, Follicular
1
Leukemia, Hairy Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Burkitt Lymphoma
1
Anus Neoplasms
1
Interventions
Carboplatin
71
pembrolizumab
70
Pemetrexed
62
Cisplatin
46
Nivolumab
28
Paclitaxel
27
durvalumab
26
Specimen Handling
25
osimertinib
23
Docetaxel
23
Magnetic Resonance Spectroscopy
21
Gemcitabine
17
Cetuximab
15
130-nm albumin-bound paclitaxel
15
atezolizumab
14
amivantamab
14
Radiotherapy
12
Radiosurgery
12
lazertinib
11
Ipilimumab
9
Bevacizumab
9
cemiplimab
8
Taxes
8
Drug Therapy
8
alectinib
7
Ramucirumab
7
Observation
7
Radiation
6
Leucovorin
5
Immunoglobulin G
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Non-Small-Cell Lung
×
Diphenhydramine
×
30 days
×
Clear all
NCT04165096
2026-05-13
MK-3475-01C
Merck Sharp & Dohme LLC
Phase 2
Completed
128 enrolled
14 charts